Security
Dynamics Special Purpose Corp. Class A Common Stock · DYNS
DYNSNASDAQCommon stockHistorical · closed Jun 8, 2022CIK 1854270Updated Oct 28, 2026
Name history
Senti Biosciences, Inc. · through May 8, 2026Senti Biosciences, Inc.\ · through Jun 28, 2022Dynamics Special Purpose Corp. · through Jun 13, 2022
Current security for this SEC filerSNTI · NASDAQ
DYNS price & chart
Historical security
This listing closed Jun 8, 2022. Live provider charts are shown only for current listings.
Current security: SNTI
About the company
SENTI-202 is a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies, such as AML and myelodysplastic syndrome (“MDS”), while sparing healthy bone marrow cells. SENTI-202 has three main components. First, SENTI-202 contains an OR GATE (providing a “kill” signal), which is an activating CAR that recognizes CD33 and/or FLT3. By targeting either or both of these antigens, SENTI-202 is designed to effectively kill both leukemic blasts and leukemia stem cells, which constitute a difficult-to-eradicate reservoir of AML disease. Second, SENTI-202 contains a NOT GATE (providing a “protect” signal), which is an inhibitory CAR that is designed to recognize healthy cells and protect those healthy cells from being killed, even if they were to express CD33 and/or FLT3, thus potentially widening the therapeutic window. Third, SENTI-202 contains calibrated-release IL-15 (providing an “enhance” signal), which is designed to significantly increase cell persistence, expansion and activity of both the CAR-NK cells and host immune cells. The NK cell…
In the news
No coverage from other publishers is available.
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Unregistered Sales of Equity Securities
Items 1.01, 1.02, 2.01, 3.02, 9.01
4 filing
4 filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 52,685,000Source | 57,721,000Source | 33,105,000Source | 68,540,000Source | 86,913,000Source | 38,241,000Source | 82,778,000Source | 102,185,000Source | 51,223,000Source | 97,841,000Source | 119,484,000Source | 180,792,000Source |
| Property, Plant and Equipment, NetUSD | 18,691,000Source | 22,218,000Source | 11,433,000Source | 19,593,000Source | 23,253,000Source | 12,100,000Source | 20,533,000Source | 24,354,000Source | 12,886,000Source | 21,289,000Source | 25,338,000Source | 56,136,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 12,243,000Source | 10,479,000Source | 6,463,000Source | 21,576,000Source | 15,860,000Source | 8,935,000Source | 33,802,000Source | 23,723,000Source | 16,420,000Source | 48,277,000Source | 35,926,000Source | 57,621,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 626,000Source |
| Assets, CurrentUSD | 18,158,000Source | 17,384,000Source | 13,007,000Source | 32,521,000Source | 44,339,000Source | 14,790,000Source | 45,213,000Source | 55,666,000Source | 23,274,000Source | 58,961,000Source | 71,200,000Source | 102,579,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 3,390,000Source |
| Operating Lease, Right-of-Use AssetUSD | 12,262,000Source | 14,470,000Source | 7,239,000Source | 12,845,000Source | 15,301,000Source | 7,818,000Source | 13,407,000Source | 15,797,000Source | 11,516,000Source | 13,948,000Source | 16,274,000Source | 18,418,000Source |
| Other Assets, NoncurrentUSD | 34,000Source | 88,000Source | 0Source | 52,000Source | 76,000Source | 5,000Source | 76,000Source | 86,000Source | 19,000Source | 105,000Source | 215,000Source | 293,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 44,564,000Source | 41,727,000Source | 36,506,000Source | 43,888,000Source | 42,765,000Source | 35,676,000Source | 44,919,000Source | 46,091,000Source | 45,634,000Source | 47,086,000Source | 52,571,000Source | 53,529,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | — | — | 0Source | — | — | 0Source | — | — | — | 0Source |
| Common Stock, Value, IssuedUSD | 3,000Source | 1,000Source | 3,000Source | 3,000Source | 1,000Source | 3,000Source | 3,000Source | 5,000Source | 3,000Source | 1,000Source | 5,000Source | 4,000Source |
| Additional Paid in CapitalUSD | 352,223,000Source | 312,517,000Source | 372,139,000Source | 350,628,000Source | 311,805,000Source | 365,355,000Source | 349,102,000Source | 312,544,000Source | 364,158,000Source | 322,782,000Source | 311,252,000Source | 300,544,000Source |
| Retained Earnings (Accumulated Deficit)USD | -344,105,000Source | -296,524,000Source | -375,543,000Source | -325,979,000Source | -267,658,000Source | -362,793,000Source | -311,246,000Source | -256,455,000Source | -358,572,000Source | -297,134,000Source | -244,344,000Source | -173,286,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | — | — | — | — | 0Source | — | — | 0Source | 1,000Source |
| Stockholders' Equity Attributable to ParentUSD | 8,121,000Source | 15,994,000Source | -3,401,000Source | 24,652,000Source | 44,148,000Source | 2,565,000Source | 37,859,000Source | 56,094,000Source | 5,589,000Source | 25,649,000Source | 66,913,000Source | 127,263,000Source |
| Liabilities and EquityUSD | 52,685,000Source | 57,721,000Source | 33,105,000Source | 68,540,000Source | 86,913,000Source | 38,241,000Source | 82,778,000Source | 102,185,000Source | 51,223,000Source | 97,841,000Source | 119,484,000Source | 180,792,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 12,027,000Source | 9,064,000Source | 15,765,000Source | 9,987,000Source | 9,068,000Source | 14,268,000Source | 10,726,000Source | 9,609,000Source | 13,974,000Source | 13,146,000Source | 12,672,000Source | 18,053,000Source |
| Operating Lease, Liability, CurrentUSD | 5,153,000Source | 4,486,000Source | 3,492,000Source | 4,979,000Source | 4,329,000Source | 5,891,000Source | 4,811,000Source | 4,178,000Source | 5,330,000Source | 4,647,000Source | 4,031,000Source | 1,988,000Source |
| Accounts Payable, CurrentUSD | 1,771,000Source | 793,000Source | 2,248,000Source | 1,020,000Source | 1,181,000Source | 1,052,000Source | 1,559,000Source | 1,624,000Source | 2,943,000Source | 1,454,000Source | 1,250,000Source | 2,267,000Source |
| Operating Lease, Liability, NoncurrentUSD | 24,968,000Source | 30,120,000Source | 12,741,000Source | 26,332,000Source | 31,311,000Source | 13,250,000Source | 27,634,000Source | 32,445,000Source | 23,561,000Source | 28,891,000Source | 33,538,000Source | 35,103,000Source |
| Other Liabilities, NoncurrentUSD | 7,569,000Source | 2,543,000Source | 8,000,000Source | 7,569,000Source | — | 8,158,000Source | 6,559,000Source | — | 8,099,000Source | 5,049,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 35,900,000Source | 98,600,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 40,942,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,315,000Source | 1,204,000Source | 5,706,000Source | 1,755,000Source | 9,670,000Source | 16,392,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | — | — | 131,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,891,000Source | 357,000Source | 1,743,000Source | 797,000Source | -290,000Source | 186,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -7,481,000Source | -14,050,000Source | -43,444,000Source | -41,397,000Source | -52,395,000Source | -34,896,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 114,000Source | 0Source | -184,000Source | 34,000Source | 30,077,000Source | -81,959,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 0Source | 196,000Source | 26,000Source | 12,038,000Source | 41,374,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -118,000Source | -414,000Source | 11,761,000Source | 53,730,000Source | 779,000Source | 118,551,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -7,485,000Source | -14,464,000Source | -31,867,000Source | 12,367,000Source | -21,539,000Source | 1,696,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 15,783,000Source | 14,040,000Source | 7,889,000Source | 25,105,000Source | 12,463,000Source | 37,351,000Source | 19,948,000Source | 51,815,000Source | 39,448,000Source | 60,987,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,551,000Source | 668,000Source | 1,048,000Source | 1,526,000Source | 1,315,000Source | 1,204,000Source | 5,706,000Source | 1,755,000Source | 11,692,000Source | 16,392,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 35,900,000Source | 98,600,000Source |
| DepreciationUSD | — | — | — | — | — | — | 688,000Source | 926,000Source | 3,637,000Source | 3,838,000Source | 3,400,000Source | 1,398,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | — | — | — | — | — | — | 0Source | 21,862,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | -12,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 1,289,000Source |
| General and Administrative ExpenseUSD | — | — | 6,432,000Source | 6,560,000Source | 6,739,000Source | 6,769,000Source | 6,233,000Source | 7,116,000Source | 26,163,000Source | 26,370,000Source | 37,176,000Source | 40,848,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -28,866,000Source | -12,750,000Source | -14,733,000Source | -4,221,000Source | -14,112,000Source | -61,438,000Source | -52,790,000Source | -83,406,000Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 12,348,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,126,000Source | -28,866,000Source | -12,750,000Source | -14,733,000Source | -4,221,000Source | -14,112,000Source | -61,438,000Source | -52,790,000Source | -71,058,000Source | -58,210,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -18,126,000Source | -28,866,000Source | — | -14,733,000Source | — | -14,112,000Source | -61,438,000Source | -55,312,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | -1,178,000Source | -13,651,000Source | 1,739,000Source | 2,065,000Source | 395,000Source | 2,285,000Source | 7,341,000Source | 8,249,000Source | 9,321,000Source | 12,419,000Source |
| Operating ExpensesUSD | — | — | 16,948,000Source | 15,215,000Source | 14,506,000Source | 16,798,000Source | 4,632,000Source | 16,397,000Source | 68,801,000Source | 61,039,000Source | 95,288,000Source | 74,915,000Source |
| Operating Lease, Lease IncomeUSD | — | — | — | 1,657,000Source | — | 1,794,000Source | — | 1,891,000Source | — | 6,608,000Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 223,000Source | -11,000Source | — | 209,000Source | 200,000Source | 178,000Source | 800,000Source | 153,000Source | -33,000Source | -32,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 1,806,000Source | 512,000Source | 728,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 0Source | 1,510,000Source | 3,050,000Source | 4,900,000Source | 0Source | 521,000Source |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss) | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 0Source | 17,000Source | 0Source | 16,000Source | 0Source | 22,000Source | 0Source | 1,978,000Source | 3,286,000Source |
| Operating Income (Loss)USD | — | — | -16,948,000Source | -15,215,000Source | -14,489,000Source | -16,798,000Source | -4,616,000Source | -16,397,000Source | -68,779,000Source | -61,039,000Source | -92,727,000Source | -70,629,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 223,000Source | -11,000Source | — | 209,000Source | 200,000Source | 178,000Source | 800,000Source | 153,000Source | -33,000Source | -32,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,126,000Source | -28,866,000Source | -12,750,000Source | -14,733,000Source | -4,221,000Source | -14,112,000Source | -61,438,000Source | -52,790,000Source | -71,058,000Source | -58,210,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.69Source | -6.31Source | -0.41Source | -0.56Source | -0.14Source | -1.41Source | -2.73Source | -12.03Source | -1.6Source | -2.23Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.69Source | -6.31Source | -0.41Source | -0.56Source | -0.14Source | -1.41Source | -2.73Source | -12.03Source | -1.6Source | -2.23Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 26,228,274Source | 4,577,122Source | 31,144,754Source | 26,081,273Source | 30,971,573Source | 10,012,908Source | 22,483,391Source | 4,595,946Source | 44,372,223Source | 26,110,785Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 26,228,274Source | 4,577,122Source | 31,144,754Source | 26,081,273Source | 30,971,573Source | 10,012,908Source | 22,483,391Source | 4,595,946Source | 44,372,223Source | 26,110,785Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 6,432,000Source | 6,560,000Source | 6,739,000Source | 6,769,000Source | 6,233,000Source | 7,116,000Source | 26,163,000Source | 26,370,000Source | 37,176,000Source | 40,848,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -28,866,000Source | -12,750,000Source | -14,733,000Source | -4,221,000Source | -14,112,000Source | -61,438,000Source | -52,790,000Source | -83,406,000Source | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | -6.31Source | — | — | — | — | — | -12.03Source | -1.88Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | -6.31Source | — | — | — | — | — | -12.03Source | -1.88Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | 12,348,000Source | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 166,000Source | 150,000Source | 55,000Source | 270,000Source | 101,000Source | 394,000Source | 927,000Source | 948,000Source | 2,864,000Source | 1,701,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -18,126,000Source | -28,866,000Source | — | -14,733,000Source | — | -14,112,000Source | -61,438,000Source | -55,312,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | -1,178,000Source | -13,651,000Source | 1,739,000Source | 2,065,000Source | 395,000Source | 2,285,000Source | 7,341,000Source | 8,249,000Source | 9,321,000Source | 12,419,000Source |
| Operating ExpensesUSD | — | — | 16,948,000Source | 15,215,000Source | 14,506,000Source | 16,798,000Source | 4,632,000Source | 16,397,000Source | 68,801,000Source | 61,039,000Source | 95,288,000Source | 74,915,000Source |
| Operating Lease, Lease IncomeUSD | — | — | — | 1,657,000Source | — | 1,794,000Source | — | 1,891,000Source | — | 6,608,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 10,516,000Source | 8,655,000Source | 7,767,000Source | 10,029,000Source | 5,281,000Source | 9,281,000Source | 37,586,000Source | 34,356,000Source | 32,150,000Source | 34,067,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss) | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-296917
Registration 333-265873
Registration 333-267390
Registration 333-285983
Registration 333-285985
Filing attachments
ef20084208_ex99-1.htm · 8-K · 2026-10-26
Exhibit 99.1 SENTI BIOSCIENCES HOLDINGS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION The following unaudited pro forma condensed consolidated financial information presents the historical financial information of Senti Biosciences Holdings, Inc. (the “Company,” “we,” “us” or “our”) adjusted to give effect to the Merger and other material transactions, as further described below. The unaudited pro forma condensed consolidated financial information has been prepared in…
Read attachment ↗d87527dex991.htm · S-3/A · 2026-09-10
Exhibit 99.1 SENTI BIOSCIENCES HOLDINGS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION The following unaudited pro forma condensed consolidated financial information presents the historical financial information of Senti Biosciences Holdings, Inc. (the “Company,” “we,” “us” or “our”) adjusted to give effect to the proposed Merger and other material transactions, as further described below. The unaudited pro forma condensed consolidated financial information has been pr…
Read attachment ↗ny20078262x1_ex107.htm · PREM14A · 2026-07-21
Exhibit 107 Calculation of Filing Fee Tables Schedule 14A (Form Type) Senti Biosciences Holdings, Inc. ( Exact Name of Registrant as Specified in its Charter ) Table 1 - Transaction Valuation Proposed Maximum Aggregate Value of Transaction Fee Rate Amount of Filing Fee ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Fees to Be Paid …
Read attachment ↗d279931dex107.htm · 8-K12B · 2026-04-24
EX-10.7 15 d279931dex107.htm EX-10.7 EX-10.7 Exhibit 10.7 Senti Biosciences Holdings, Inc. Amended and Restated 2022 Employee Stock Purchase Plan ADOPTED BY THE BOARD OF DIRECTORS: April 24, 2026 APPROVED BY THE STOCKHOLDERS: April 24, 2026 GENERAL; PURPOSE. The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series …
Read attachment ↗d279931dex41.htm · 8-K12B · 2026-04-24
EX-4.1 7 d279931dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 SPECIMEN COMMON STOCK CERTIFICATE NUMBER C–[ ] SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP [ ] SENTI BIOSCIENCES HOLDINGS, INC. COMMON STOCK THIS CERTIFIES THAT [ ] is the owner of fully paid and non-assessable shares of common stock, par value US $0.0001 per share, of Senti Biosciences Holdings, Inc., a Delaware corporation (the “Company”), subject to the Company’s certificate of incorporati…
Read attachment ↗d279931dex42.htm · 8-K12B · 2026-04-24
EX-4.2 8 d279931dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 DESCRIPTION OF SECURITIES The following description summarizes certain important terms of the capital stock of Senti Biosciences Holdings, Inc. (the “Company,” “Senti,” “we,” “us,” and “our”) as of the date of this Current Report on Form 8-K (the “8-K”) as specified in our Amended and Restated Certificate of Incorporation (as amended and/or restated from time to time, the “Charter”) and our Amended and Restated Bylaws (the “Bylaws”). Bec…
Read attachment ↗